PVCT has had a rocky ride since my last post. It is now down to where it was a year ago. However the actual progress on its drug has been only positive. It is the victim of attacks by shorts who do not care about fundamentals. PVCT does not need capital for the next 15 months, so it can continue even with a low stock price. It has now announced its plans for a Phase III study for PV-10 for melanoma using standard protocols. Based on its results so far in its Phase II study (and other sources), it should do very well.
There are several potential catalysts for a big rise in price, even before a successful P3 study. There are ongoing talks with companies in India and China. Now that their Phase III path is clear, they should be able to sign a deal. There is also expected information about PH-10, their skin drug. They have $19 million in the bank. Their value is certainly many times more than the current stock price.